Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12967678 | 0.80 | LMNA (0.37) | NOTUMSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL12967765 | 0.77 | NOTUM (0.34) | NOTUMALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL28294972 | 0.77 | CA1 (0.38) | MCL1NOTUMALDH1A1KDM4EHPGD | |
| SCHEMBL23012186 | 0.72 | TAS2R14 (0.57) | — | |
| SCHEMBL263529 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL8077868 | 0.66 | NOTUM (0.45) | NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL30798629 | 0.66 | NOTUM (0.45) | NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2147013 | 0.65 | — | — | |
| SCHEMBL69630 | 0.65 | ALDH1A1 (0.39) | NOTUMSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL163291 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| EP-2773615-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| CN-104039766-A | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD | 2014-09-10 | — | — | CN | disclosed |
| WO-2013064543-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | NR1H4, HAVCR2, NR1H3 | MCL1 3055/4885NOTUM 4043/4885SMN1; SMN2 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.